

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
16/SS/0115	206867	A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)	Yes	4	4	Yes	13/02/2018	1	13/02/2018	1	Withdrawn By Sponsor	Closed early due to lack of drug efficacy
15/SC/0659	189114	A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subject's who are Asymptomatic At Risk for Developing Alzheimer's Disease	Yes	10	10	No			17/05/2018	1	Withdrawn By Sponsor	Sponsor withdrew the study due to side effects.
16/LO/1297	206641	Protocol I8D-MC-AZETA Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of	Yes	10	10	No			12/06/2018	7	Withdrawn By Sponsor	Sponsor discontinued the study due to not meeting its end point

LY3314814 in Mild
Alzheimer's
Disease Dementia
(The Daybreak
study)

16/LO/1820	212826	Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa	Yes	9	9	Yes	08/08/2018	9	08/08/2018	9	Recruitment Finished
------------	--------	---	-----	---	---	-----	------------	---	------------	---	-------------------------